Skip to main content
Nathan Fowler, MD, Oncology, Houston, TX, University of Texas M.D. Anderson Cancer Center

NathanH.FowlerMD

Oncology Houston, TX

Physician

Dr. Fowler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Fowler's full profile

Already have an account?

Education & Training

  • MedStar Health/Georgetown University Hospital
    MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2004 - 2007
  • University of Texas Medical Branch Hospitals
    University of Texas Medical Branch HospitalsResidency, Internal Medicine, 2001 - 2004
  • University of Texas Medical Branch School of Medicine
    University of Texas Medical Branch School of MedicineClass of 2001
  • University of Houston
    University of HoustonBS (Honors), Biology

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • TX State Medical License
    TX State Medical License 2007 - 2025
  • OK State Medical License
    OK State Medical License 2020 - 2021
  • DC State Medical License
    DC State Medical License 2004 - 2008

Awards, Honors, & Recognition

  • Patient's Choice Award Registry, 2015-2019
  • Waun Ki Hong Award in Team Science MD Anderson Cancer Center, 2018
  • Most Compassionate Doctor Award Registry, 2009, 2011-2018
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Venetoclax, Bendamustine, and Rituximab in Patients with Relapsed or Refractory NHL: A Phase 1b Dose-Finding Study  
    N Fowler, E Reid, L J Nastoupil, Annals of Oncology

Abstracts/Posters

  • Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus L...
    Nathan H Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL
    Nathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)
    Nathan H Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Realizing the Promise of Novel Therapeutics in NHL: A MasterClass and Tumor Board on Clinical Decision-Making in FL, MCL, and DLBCL 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed p... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • BostonGene and Sylvester Comprehensive Cancer Center at the University of Miami Announce Collaboration
    BostonGene and Sylvester Comprehensive Cancer Center at the University of Miami Announce CollaborationMay 23rd, 2023
  • BostonGene Announces Publication in Cell Reports Revealing Spatial Heterogeneity in the Tumor Microenvironment of Multiregional Clear Cell Renal Cell Carcinoma Biopsies
    BostonGene Announces Publication in Cell Reports Revealing Spatial Heterogeneity in the Tumor Microenvironment of Multiregional Clear Cell Renal Cell Carcinoma BiopsiesOctober 4th, 2022
  • BostonGene Showcases Lifesaving Cancer Diagnostic and Treatment Recommendation Test at the 81st Annual Meeting of the Japanese Cancer Association
    BostonGene Showcases Lifesaving Cancer Diagnostic and Treatment Recommendation Test at the 81st Annual Meeting of the Japanese Cancer AssociationSeptember 21st, 2022
  • Join now to see all

Hospital Affiliations